Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00975975
Other study ID # 0908-04; IUCRO-0256
Secondary ID
Status Completed
Phase Phase 2
First received September 11, 2009
Last updated January 28, 2016
Start date September 2009
Est. completion date November 2013

Study information

Verified date January 2016
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known as graft-versus-host disease (GVHD). GVHD is a complication in which the cells of the transplanted bone marrow react against organs and tissues.


Description:

This study is for patients with a blood condition or myelodysplasia (bone marrow disease) which has either not responded to treatment or is not treatable by conventional/routine medical treatments. Bone marrow transplantation is a medical treatment that involves giving high doses of chemotherapy followed by the transplantation of the blood-forming and immune cells from a relative or from a "matched" unrelated person through the National Marrow Donor Program, in an attempt to cure disease in the recipient (the person receiving the donated cells). Nonmyeloablative (bone-marrow preservation) bone marrow transplantation is a relatively new technique in which lower than usual doses of chemotherapy are given before transplantation, in hopes of reducing adverse side effects of the chemotherapy in transplant patients. Nonmyeloablative bone marrow transplantation has several advantages which doctors have determined are beneficial for this condition.

This research is being done because the complication of graft-versus-host disease can be bad for a person and there is no completely safe and effective way to prevent this complication. We know that cyclosporine helps but would like to know if the addition of basiliximab, given with cyclosporine, will decrease the incidence and/or severity of graft-versus-host disease after a transplant known as nonmyeloablative or "mini" transplant.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date November 2013
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Acute myelogenous leukemia:

- Second or subsequent remission; patient over 18 yrs of age.

- Relapsed after autologous HC transplant, over 18 years of age.

- First remission, Philadelphia chromosome + over age 18.

- Secondary AML, in first or subsequent remissions.

- Acute lymphocytic leukemia:

- Philadelphia chromosome + over the age of 50, first or subsequent remission.

- Relapse following Autologous HC transplantation, ages over 50.

- Second or subsequent remission over the age of 50

- Chronic myelogenous leukemia:

- First or second chronic phase over the age of 18.

- Accelerated phase over the age of 18.

- Must have failed or been intolerant to a standard tyrosine kinase inhibitor.

- Chronic lymphocytic leukemia:

- Failed nucleoside-based therapy, ages >18.

- Myelodysplasia:

- All-risk categories, age greater than 18.

- Non-Hodgkin's Lymphoma, less than 76 years of age

- Relapsed diffuse aggressive NHL (intermediate and high grade) that fails to achieve CR or PR to conventional salvage chemotherapy.

- Aggressive NHL includes diffuse large B cell lymphoma, diffuse mixed small and large cell lymphoma, follicular lymphoma for grade 3 (follicular large cell lymphoma), T or B cell lymphoblastic lymphoma, diffuse small noncleaved (Burkett's or Burkett-like ) lymphoma, mantle cell lymphoma, peripheral T cell lymphoma, anaplastic large cell lymphoma, and other diffuse aggressive lymphomas that are not otherwise classifiable

- Aggressive NHL that has relapsed following autologous HCT. Patients that respond to additional treatment for post-transplant relapse are eligible.

- Aggressive NHL that does not achieve CR or PR with primary chemotherapy (i.e., primary induction failure).

- Low-grade lymphoma refractory to standard therapy, including the following:

1. small cell lymphocytic lymphoma,

2. follicular lymphoma of grades 1 and 2 (follicular small cleaved and follicular mixed small and large cell lymphoma)

3. marginal cell lymphoma, splenic lymphoma),

4. lymphoplasmacytic lymphoma and

5. other lymphomas not otherwise classifiable.

- Patients with low-grade lymphoma must have experienced progressive disease after receiving three or more of the following regimens:

- alkylator-based therapy (cyclophosphamide/ vincristine/ prednisone) chlorambucil, monoclonal antibody based therapy (e.g., rituximab, Campath-1H, radiolabelled CD20+ antibodies);

- nucleoside analog-based therapy (e.g., fludarabine, cladribine).)

- Patients with marginal zone lymphoma or gastric MALT type associated with Helicobacter pylori infection must have progressed after receiving appropriate antibiotic therapy as well as three or more regimens as described above

- Mantle cell, ages 18-75.

- Hodgkin's Disease, ages 18-75.

- Relapsed or refractory disease after autologous transplant.

- Multiple Myeloma, ages 18-75

- Recurrent disease after two medical therapies

- Relapse following autologous transplant

- Myelofibrosis, age greater than 18 years

- Severe aplastic anemia (refractory to immunosuppressive therapy); age greater than 18 years

- Patients with aplastic anemia must have marrow cellularity = 10% plus 2 of the following:

1. Absolute granulocyte count <500/mm3

2. Corrected reticulocyte count <1%

3. Untransfused platelet count <20,000/mm3 on at least 2 occasions

4. Hemoglobin <9 g/dL (adults) or < 8 g/dL (children) on at least 2 occasions

- Paroxysmal nocturnal hemoglobinuria; age greater than 18 years.

- Renal function: creatinine greater than 2.5

- Donor Requirement:

- Must have a fully HLA-matched (10 of 10 Antigen matched) related or unrelated donor, eighteen years of age or older, who is capable of undergoing GCSF mobilization and apheresis

Exclusion Criteria:

- Active CNS disease (the presence of leukemic blasts in the CSF)

- Pregnancy or breast-feeding.

- Inability to give informed consent.

- AST, ALT, total bilirubin >3x upper limit of normal.

- Creatinine > 2 or creatinine clearance < 50mL/hr. If patient has a creatinine of > 2 or creatinine clearance < 50mL/hr and it is due to the disease process then the patient will not be excluded based on this.

- Fractional shortening by echocardiogram not within normal limits per institution or LVEF of < 40 %.

- Pulmonary function: DLCO not within institutional normal limits or DLCO less than 45% of normal predicted, corrected for anemia

- Prior allogeneic transplant.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Anemia, Aplastic
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Hemoglobinuria
  • Hemoglobinuria, Paroxysmal
  • Hodgkin Disease
  • Hodgkin's Disease
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Myelodysplasia
  • Myelodysplastic Syndromes
  • Myelofibrosis
  • Non-Hodgkin's Lymphoma
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Preleukemia

Intervention

Drug:
Basiliximab
Basiliximab given 1 time on Day +7 or Day +9.

Locations

Country Name City State
United States Indiana University Cancer Center Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Grade 3-4 Acute GVHD Rate The percent of patients where a patient experienced a Grade 3 or 4 acute GVHD Transplant (Day 0) up to 1 year Yes
Secondary Time to Neutrophil Engraftment Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l. Patients who did not have neutrophil engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided. Transplant (Day 0) up to 1 year No
Secondary Time to Platelet Engraftment Time to platelet engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of platelets is defined as the time from day 0 to the first of seven consecutive days after transplantation during which the platelet count is at least 20 x109/l without transfusion support. Patients who did not have platelet engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided. Transplant (Day 0) up to 1 year No
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1